Skip to Main

Megan DeFauw is a core member of Boston Consulting Group’s Health Care and Operations practices. She focuses on biopharma and medtech manufacturing and supply chain. Since joining BCG in 2011, Megan has worked extensively in strategy and operations topics including network design, quality, organization design, large-scale transformation, post-merger integration, and divestitures. Megan leads the firm’s work in quality for North America, as well as for cost transformation in health care operations.

Megan has worked with pharmaceutical and medtech clients across all phases of acquisitions and divestitures, as well as manufacturing network strategy and redesign, operations transformation, and quality remediation and transformation.

AREAS OF EXPERTISE

EDUCATION

  • PhD, industrial and operations engineering, University of Michigan
  • MSE, industrial and operations engineering, University of Michigan
  • BSE, industrial and operations engineering, University of Michigan

Publications and Videos

" "

Tackling the Talent Challenge in Biotech Acquisitions

To retain target biotech company employees—arguably as vital to success as the pipeline being acquired—biopharmas need talent strategies that focus on three key areas.
""

Health Care Resilience in Three Key Moves

Biopharma and medtech companies must act now to ensure their ability to mitigate disruptions across the value chain.
Biopharma Carve-Outs Are Tricky - rectangle

Biopharma Carve-Outs Are Tricky. Here’s How to Get Them Right.

Through carve-outs, companies can create value, streamline portfolios, and reduce complexity. But the ultimate success of a deal hinges on focused, proactive execution.
" "

Dispel These Myths to Maximize Value in Small and Midsize Biopharma M&A

Acquirers need to plan their integrations carefully and act quickly, but too often they delay decision making and destroy value.
" "

Planning for the Unpredictable in Health Care Supply Chains

As the current crisis demonstrates, biopharma and medtech companies need to safeguard their networks against unanticipated disruptions. Here’s how.
" "

Designing Resilience into Global Supply Chains

To address flaws exposed by the pandemic, companies should accelerate efforts to revamp their worldwide manufacturing and sourcing networks—even if that means extra cost.
Redrawing the Map of Global Trade

Redrawing the Map of Global Trade

Even when the global economy fully recovers, the international trade landscape will look dramatically different in the years ahead than it did before the pandemic.